Your browser is no longer supported. Please, upgrade your browser.
Settings
PCRX Pacira BioSciences, Inc. daily Stock Chart
PCRX [NASD]
Pacira BioSciences, Inc.
Index- P/E207.38 EPS (ttm)0.18 Insider Own0.90% Shs Outstand42.42M Perf Week-5.46%
Market Cap1.61B Forward P/E17.68 EPS next Y2.15 Insider Trans-16.82% Shs Float41.39M Perf Month-4.26%
Income7.60M PEG5.32 EPS next Q0.34 Inst Own- Short Float7.91% Perf Quarter-13.51%
Sales372.50M P/S4.32 EPS this Y98.90% Inst Trans1.53% Short Ratio6.35 Perf Half Y-5.71%
Book/sh8.26 P/B4.59 EPS next Y48.72% ROA1.10% Target Price51.33 Perf Year-18.12%
Cash/sh6.89 P/C5.51 EPS next 5Y39.00% ROE2.40% 52W Range35.07 - 55.00 Perf YTD-11.79%
Dividend- P/FCF30.20 EPS past 5Y64.10% ROI2.60% 52W High-28.51% Beta1.11
Dividend %- Quick Ratio4.10 Sales past 5Y31.60% Gross Margin74.30% 52W Low12.12% ATR1.52
Employees518 Current Ratio4.80 Sales Q/Q22.00% Oper. Margin6.10% RSI (14)39.40 Volatility2.91% 3.92%
OptionableYes Debt/Eq0.87 EPS Q/Q4.80% Profit Margin2.00% Rel Volume0.65 Prev Close37.95
ShortableYes LT Debt/Eq0.87 EarningsAug 08 BMO Payout0.00% Avg Volume515.04K Price39.32
Recom2.50 SMA20-6.13% SMA50-7.01% SMA200-6.70% Volume286,427 Change3.61%
Jun-11-19Initiated Barclays Overweight $52
May-06-19Upgrade Mizuho Underperform → Neutral $29 → $38
May-02-19Upgrade Stifel Sell → Hold $45
Feb-01-19Downgrade Mizuho Neutral → Underperform
Aug-06-18Downgrade BofA/Merrill Buy → Neutral
Apr-09-18Reiterated H.C. Wainwright Buy $45 → $48
Mar-21-18Reiterated Mizuho Neutral $44 → $31
Feb-16-18Downgrade Needham Buy → Hold
Jan-19-18Initiated Seaport Global Securities Buy $50
Jan-04-18Reiterated Canaccord Genuity Buy $42 → $46
Jan-03-18Initiated Leerink Partners Mkt Perform $46
Dec-18-17Initiated JP Morgan Neutral $47
Nov-29-17Downgrade Mizuho Buy → Neutral $53 → $44
Nov-09-17Resumed H.C. Wainwright Buy $52
Oct-26-17Downgrade Janney Neutral → Sell
Oct-19-17Reiterated Needham Buy $55 → $52
Sep-28-17Initiated Goldman Neutral $41
Sep-07-17Initiated Oppenheimer Perform
Aug-22-17Initiated Needham Buy $55
Aug-21-17Upgrade Janney Sell → Neutral
Aug-19-19 09:30AM  ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Aug-16-19 07:15PM  Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $503,038 of Shares GuruFocus.com
Aug-09-19 11:02AM  Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-08-19 06:12PM  Pacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript Motley Fool
09:55AM  Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates Zacks
08:00AM  Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Aug-07-19 07:30AM  Pacira BioSciences to Present at the 2019 Wedbush Pacgrow Healthcare Conference GlobeNewswire
Aug-01-19 10:32AM  Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-31-19 07:02AM  Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility? Simply Wall St.
Jul-30-19 07:30AM  Pacira to Report Second Quarter 2019 Financial Results on Thursday August 8, 2019 GlobeNewswire
Jul-25-19 10:33AM  Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Jun-28-19 09:15AM  DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model Zacks Small Cap Research
Jun-26-19 06:17PM  Pacira Gets EMA Acceptance for Pain Management Drug Exparel Zacks
07:30AM  New Retrospective Analysis Shows EXPAREL Associated with Significantly Less Opioid Use Following Third Molar Extraction GlobeNewswire
Jun-25-19 07:30AM  Pacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency GlobeNewswire
06:39AM  Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount? Simply Wall St.
Jun-24-19 09:30AM  JAZZ or PCRX: Which Is the Better Value Stock Right Now? Zacks
Jun-19-19 07:30AM  Pacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President GlobeNewswire
Jun-18-19 05:48AM  Edited Transcript of PCRX earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-14-19 05:59PM  Heres What Hedge Funds Think About Pacira Pharmaceuticals Inc (PCRX) Insider Monkey
Jun-12-19 07:30AM  New Analysis Shows Use of EXPAREL Associated with Improved Clinical and Economic Outcomes Following Hip Replacement Surgery GlobeNewswire
Jun-04-19 07:30AM  Pacira Announces Publication of Pivotal Study of EXPAREL as a Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery GlobeNewswire
Jun-01-19 09:32AM  Why Is Pacira (PCRX) Down 7.2% Since Last Earnings Report? Zacks
May-30-19 07:48AM  Cara Shares Up on Positive Phase III Data for Itchiness Drug Zacks
May-28-19 07:30AM  Pacira BioSciences to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-22-19 01:11PM  How Financially Strong Is Pacira BioSciences, Inc. (NASDAQ:PCRX)? Simply Wall St.
May-20-19 09:30AM  JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now? Zacks
May-07-19 08:00AM  Pacira BioSciences to Present at Two Healthcare Conferences in May GlobeNewswire
07:30AM  Phase 4 Study Demonstrates Superiority of EXPAREL plus Bupivacaine versus Bupivacaine Alone in Cesarean Section Procedures GlobeNewswire
May-03-19 11:30AM  Pacira Pharmaceuticals, Inc. (PCRX) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 09:00PM  Pacira BioSciences Rocks in Q1 With Strong Momentum for Pain Drug Exparel Motley Fool
09:25AM  Pacira (PCRX) Misses Q1 Earnings Estimates Zacks
08:17AM  Pacira: 1Q Earnings Snapshot Associated Press
08:00AM  Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million GlobeNewswire
May-01-19 01:46PM  Pacira Pre-Earnings Calls Hot as Rival Biotech Sinks Schaeffer's Investment Research +16.15%
12:00PM  Why Heron Therapeutics and Pacira BioSciences Are Moving in Opposite Directions Today Motley Fool
11:53AM  Is Pacira Pharmaceuticals Inc (PCRX) A Good Stock To Buy ? Insider Monkey
Apr-26-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Pacira (PCRX) Zacks
Apr-25-19 10:33AM  Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
07:30AM  Pacira to Report First Quarter 2019 Financial Results on Thursday May 2, 2019 GlobeNewswire
Apr-22-19 12:41PM  Read This Before Selling Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Simply Wall St. +5.27%
Apr-09-19 04:01PM  Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System GlobeNewswire
Apr-02-19 07:30AM  Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
Mar-30-19 09:30AM  Why Is Pacira (PCRX) Down 7.6% Since Last Earnings Report? Zacks
Mar-25-19 06:00AM  Pacira's New Steps to Pain Treatment MoneyShow
Mar-21-19 06:30AM  HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results CNW Group
Mar-15-19 03:16PM  Did Changing Sentiment Drive Pacira Pharmaceuticalss (NASDAQ:PCRX) Share Price Down By 43%? Simply Wall St.
Mar-13-19 07:30AM  New Analysis Shows Enhanced Recovery Pathway Including EXPAREL Infiltration Facilitates Rapid Discharge, High Satisfaction, and Limited Opioid Use in Medicare Patients Undergoing Total Joint Replacement GlobeNewswire
Mar-07-19 12:02AM  Edited Transcript of PCRX earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 02:41PM  The Funded: A look at women in startups and more than $400M in midweek funding American City Business Journals
08:00AM  Factors of Influence in 2019, Key Indicators and Opportunity within Greif, GCP Applied Technologies, salesforce.com, inc, Chubb, Pacira Pharmaceuticals, and FARO Technologies New Research Emphasizes Economic Growth GlobeNewswire
Mar-05-19 05:05PM  [$$] Pacira Pharmaceuticals Strikes $220 Million Deal to Buy Myoscience The Wall Street Journal
08:59AM  Pacira stock down 1.9% after company announces MyoScience acquisition MarketWatch
07:00AM  Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control GlobeNewswire
Mar-04-19 09:54AM  Pacira (PCRX) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-28-19 01:54PM  Pacira Pharmaceuticals Inc (PCRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:00AM  Pacira Reports Record Fourth Quarter and Full Year Revenues GlobeNewswire
Feb-21-19 07:30AM  Pacira to Report 2018 Financial Results on Thursday February 28, 2019 GlobeNewswire
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-12-19 10:40AM  Why Pacira (PCRX) Could Beat Earnings Estimates Again Zacks
09:53AM  Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings Zacks
07:30AM  Pacira Expands EXPAREL Manufacturing Capacity to Meet Growing Demand GlobeNewswire
Feb-07-19 11:48AM  Should You Be Concerned About Pacira Pharmaceuticals, Inc.s (NASDAQ:PCRX) Historical Volatility? Simply Wall St.
Jan-17-19 07:06PM  Pacira's Study on Exparel Label Expansion Meets Endpoints Zacks
Jan-16-19 07:30AM  EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients GlobeNewswire
Jan-04-19 07:25AM  New Research Coverage Highlights LKQ, Pacira Pharmaceuticals, WellCare Health Plans, Masimo, Workday, and Potbelly Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-03-19 05:43PM  Cara (CARA) Up on IDMC's Recommendation to Continue Trial Zacks -9.52%
07:30AM  Pacira Reports Preliminary 2018 Net EXPAREL® Sales of $331 Million GlobeNewswire
Jan-02-19 11:39AM  An Intrinsic Calculation For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shows Its 34.81% Undervalued Simply Wall St.
09:35AM  Pacira Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-18 07:30AM  New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients GlobeNewswire
Dec-10-18 10:23AM  Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com Zacks
Dec-09-18 07:39PM  Pacira Pharmaceuticals Inc (PCRX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-07-18 07:30AM  Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-30-18 09:15AM  Lilly (LLY) Hits Fresh High: Is There Still Room to Run? Zacks
Nov-27-18 07:30AM  New Data Show EXPAREL Plays a Key Role in Achieving Significant Reductions in Opioid Use, Hospital Stay and Total Hospitalization Costs Following Painful Knee Replacement Surgery GlobeNewswire
Nov-23-18 01:11PM  Is Pacira Pharmaceuticals Incs (NASDAQ:PCRX) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-16-18 07:30AM  Pacira Pharmaceuticals CMO Presents at FDA Advisory Committee Meeting Focused on Assessment of Opioid-Sparing Outcomes in Clinical Trials GlobeNewswire
Nov-09-18 05:47PM  Edited Transcript of PCRX earnings conference call or presentation 1-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 08:20AM  Report: Developing Opportunities within Rayonier Advanced Materials, Health Insurance Innovations, Columbus McKinnon, A. O. Smith, Pacira Pharmaceuticals, and Altice Future Expectations, Projections Moving into 2018 GlobeNewswire
07:30AM  Pacira Pharmaceuticals to Present at Healthcare Conferences in November GlobeNewswire
Nov-05-18 10:38AM  Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates Zacks
Nov-02-18 02:12PM  Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPAREL GlobeNewswire
Nov-01-18 08:56AM  Pacira: 3Q Earnings Snapshot Associated Press +6.69%
08:00AM  Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-30-18 07:30AM  Aetna Offers Expanded Coverage for EXPAREL® in Select Ambulatory Surgical Centers GlobeNewswire
Oct-25-18 07:30AM  Pacira to Report Third Quarter 2018 Financial Results on Thursday November 1, 2018 GlobeNewswire
Oct-17-18 08:25AM  Recent Analysis Shows Repligen, SpartanNash, AZUL SA, Pacira Pharmaceuticals, Ichor, and Scorpio Tankers Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-11-18 07:30AM  New Research Reveals Potency and Quantity of Opioids Prescribed for Postsurgical Pain Poses Danger to Patients, their Families and Friends GlobeNewswire
Sep-28-18 08:31AM  Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher Zacks
Sep-27-18 08:41AM  Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher Zacks
08:37AM  Catalyst Pharmaceuticals (CPRX) Catches Eye: Stock Jumps 6.3% Zacks
Sep-26-18 11:14AM  Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status Zacks
Sep-20-18 11:40AM  Molecular Templates Surges 50%, Inks Cancer Deal With Takeda Zacks
08:53AM  Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options Zacks
08:00AM  Today's Research Reports on Trending Tickers: Pacira Pharmaceuticals and OPKO Health ACCESSWIRE
Sep-19-18 10:28AM  Are Pacira Pharmaceuticals Incs (NASDAQ:PCRX) Interest Costs Too High? Simply Wall St. +7.31%
Sep-18-18 11:18AM  United Therapeutics In-Licenses Rights to IPF Candidate Zacks
Sep-14-18 08:28PM  Edited Transcript of PCRX earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
03:55PM  Pacira Shares Look Expensive, Stifel Says In Bearish Initiation Benzinga
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. has collaboration with Aetna. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STACK DAVID MCEO and ChairmanAug 15Option Exercise10.8112,849138,898169,148Aug 16 04:19 PM
STACK DAVID MCEO and ChairmanAug 15Sale39.1512,849503,092156,299Aug 16 04:19 PM
Williams Kristen MarieChief Administrative OfficerAug 14Sale39.496,252246,89119,193Aug 16 04:15 PM
STACK DAVID MCEO and ChairmanJul 08Sale42.8813,115562,377156,299Jul 10 05:08 PM
STACK DAVID MCEO and ChairmanJun 11Option Exercise3.0724,00073,560169,231Jun 13 05:16 PM
Riker Lauren BullaroVice President, FinanceJun 10Sale44.282,12694,13910,042Jun 12 05:12 PM
Scranton RichardChief Scientific OfficerJun 05Sale43.504,114178,95911,061Jun 06 05:01 PM
WINSTON ROYChief Clinical OfficerJun 04Sale42.9172230,98116,539Jun 06 05:08 PM
Williams Kristen MarieCAO and General CounselJun 04Sale42.912,529108,51919,845Jun 06 05:06 PM
STACK DAVID MCEO and ChairmanJun 04Sale42.9112,385531,440121,531Jun 06 05:03 PM
Scranton RichardChief Scientific OfficerJun 04Sale42.774,926210,66215,175Jun 06 05:01 PM
Riker Lauren BullaroVice President, FinanceJun 04Sale42.9196741,49410,268Jun 06 04:58 PM
Reinhart Charles A. IIIChief Financial OfficerJun 04Sale42.911,10647,45811,936Jun 06 04:55 PM
McLoughlin DennisChief Commercial OfficerJun 04Sale42.911,09947,15813,822Jun 06 04:50 PM
LARANJEIRA CHARLES ANTHONYSVP, Technical OperationsJun 04Sale42.9143018,4515,367Jun 06 04:44 PM
HASTINGS PAUL JDirectorJun 04Sale42.6678233,3602,747Jun 06 04:39 PM
Scranton RichardChief Scientific OfficerJun 03Option Exercise10.7515,510166,79035,611Jun 05 04:21 PM
Scranton RichardChief Scientific OfficerJun 03Sale43.2115,510670,18720,101Jun 05 04:21 PM
Kronenfeld Mark A.DirectorMar 06Buy38.971,70066,24410,277Mar 08 04:17 PM
STACK DAVID MCEO and ChairmanDec 18Option Exercise3.5512,00042,600133,683Dec 20 04:30 PM
Wicki AndreasDirectorDec 13Sale46.188,720402,692950,362Dec 14 05:47 PM
Wicki AndreasDirectorDec 12Sale47.845,807277,803959,082Dec 14 05:47 PM
PACE GARY WDirectorNov 19Buy46.184,500207,81032,819Nov 21 04:07 PM
Wicki AndreasDirectorNov 19Sale47.0899046,605964,889Nov 21 05:19 PM
Wicki AndreasDirectorNov 16Sale46.8325,6001,198,775965,879Nov 19 07:17 PM
STACK DAVID MCEO and ChairmanNov 15Sale47.3915,000710,801121,683Nov 19 04:06 PM
Wicki AndreasDirectorNov 15Sale47.6444,8982,138,811991,479Nov 19 07:17 PM
Wicki AndreasDirectorNov 12Sale49.835,478272,9801,036,377Nov 14 08:09 PM
Wicki AndreasDirectorNov 09Sale50.2390645,5081,041,855Nov 13 08:35 PM
Wicki AndreasDirectorNov 08Sale51.1357,3392,931,5831,042,761Nov 13 08:35 PM
PACE GARY WDirectorNov 07Buy51.294,000205,16028,319Nov 09 04:30 PM
Riker Lauren BullaroVice President, FinanceNov 02Option Exercise10.341,00010,34011,474Nov 06 04:25 PM
Riker Lauren BullaroVice President, FinanceNov 02Sale54.351,00054,35010,474Nov 06 04:25 PM
STACK DAVID MCEO and ChairmanOct 11Option Exercise2.9045,000130,650136,683Oct 15 04:30 PM
Riker Lauren BullaroVice President, FinanceSep 24Option Exercise10.341,00010,34011,474Sep 26 05:13 PM
Riker Lauren BullaroVice President, FinanceSep 24Sale50.701,00050,70010,474Sep 26 05:13 PM
Kronenfeld Mark A.DirectorAug 28Buy44.611,00044,6118,577Aug 30 04:34 PM
Riker Lauren BullaroVice President, FinanceAug 22Sale44.481,66774,14810,474Aug 24 04:59 PM